
NuVasive NUVA
Quarterly report 2023-Q2
added 08-02-2023
NuVasive Book Value 2011-2026 | NUVA
Book value is a financial metric that reflects the value of a company's assets minus its liabilities as of a specific date, according to accounting records. In simple terms, it is the amount that would remain for the owners of the company if all assets were sold and all debts paid off.What is included in book value
- Assets — all company resources: real estate, equipment, inventory, cash, accounts receivable, and others.
- Liabilities — all debts and financial obligations: loans, accounts payable, taxes, and other obligations.
- Assessment of the company's "real" value
Book value shows how much the company is worth according to accounting data, that is, the value of its property taking debts into account. - Comparison with market capitalization
Comparing book value and the market price of shares helps to understand whether the company is overvalued or undervalued by the market. - Indicator of financial stability
If the book value is high, it indicates the company has significant assets, which reduces risks for investors. - Key component for financial ratios
Many metrics, such as the price-to-book ratio (P/B), use book value to analyze the attractiveness of shares.
Annual Book Value NuVasive
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2.22 B | 2.15 B | 2.69 B | 915 M | 835 M | 799 M | 701 M | 702 M | 648 M | 605 M | 538 M | 505 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 2.69 B | 505 M | 1.11 B |
Quarterly Book Value NuVasive
| 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2.09 B | 2.17 B | 2.22 B | 2.17 B | - | 2.16 B | 2.15 B | 2.13 B | 2.15 B | 2.16 B | 2.69 B | 2.69 B | 2.69 B | 2.69 B | 1.89 B | 1.89 B | 1.89 B | 1.89 B | 1.71 B | 1.71 B | 1.71 B | 1.71 B | 1.64 B | 1.64 B | 1.64 B | 1.64 B | 1.57 B | 1.57 B | 1.57 B | 1.57 B | 1.3 B | 1.3 B | 1.3 B | 1.29 B | 1.34 B | 1.34 B | 1.34 B | 1.34 B | 1.18 B | 1.18 B | 1.18 B | 1.18 B | 1.16 B | 1.16 B | 1.16 B | 1.16 B | 1.12 B | 1.12 B | 1.12 B | 1.12 B |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 2.69 B | 1.12 B | 1.67 B |
Book Value of other stocks in the Medical devices industry
| Issuer | Book Value | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
EDAP TMS S.A.
EDAP
|
40.9 M | $ 4.32 | 2.86 % | $ 162 M | ||
|
GenMark Diagnostics, Inc.
GNMK
|
196 M | - | - | $ 1.77 B | ||
|
Avinger
AVGR
|
-6.2 M | - | -20.74 % | $ 369 K | ||
|
Axonics Modulation Technologies
AXNX
|
638 M | - | - | $ 3.31 B | ||
|
Eargo
EAR
|
101 M | - | - | $ 10.2 M | ||
|
Lianluo Smart Limited
LLIT
|
272 M | - | 24.59 % | $ 44.8 M | ||
|
Allied Healthcare Products
AHPI
|
19.7 M | - | 3.58 % | $ 2.21 M | ||
|
Obalon Therapeutics, Inc.
OBLN
|
25.5 M | - | -5.86 % | $ 30.6 M | ||
|
ClearPoint Neuro
CLPT
|
28 M | $ 12.67 | 3.51 % | $ 359 M | ||
|
Apollo Endosurgery
APEN
|
32.6 M | - | - | $ 475 M | ||
|
Alphatec Holdings
ATEC
|
791 M | $ 7.75 | -1.77 % | $ 1.16 B | ||
|
Aziyo Biologics
AZYO
|
27.7 M | - | 1.37 % | $ 20.5 M | ||
|
IRIDEX Corporation
IRIX
|
4.92 M | $ 1.05 | 1.94 % | $ 17.8 M | ||
|
BioSig Technologies
BSGM
|
133 M | - | 37.08 % | $ 85.7 M | ||
|
BIOLASE
BIOL
|
1.96 M | - | -13.19 % | $ 166 K | ||
|
Conformis
CFMS
|
54.2 M | - | - | $ 16.4 M | ||
|
Cardiovascular Systems
CSII
|
249 M | - | 0.15 % | $ 844 M | ||
|
Helius Medical Technologies
HSDT
|
301 M | $ 1.91 | -6.62 % | $ 42.1 M | ||
|
CryoLife, Inc.
CRY
|
58.1 M | - | -4.14 % | $ 702 M | ||
|
CHF Solutions, Inc.
CHFS
|
6.23 M | - | 1.15 % | $ 34.5 M | ||
|
Cytosorbents Corporation
CTSO
|
5.9 M | $ 0.49 | -0.99 % | $ 30.5 M | ||
|
LENSAR
LNSR
|
-12.2 M | $ 5.8 | -3.33 % | $ 69.4 M | ||
|
OrthoPediatrics Corp.
KIDS
|
347 M | $ 17.17 | -3.59 % | $ 403 M | ||
|
Delcath Systems
DCTH
|
111 M | $ 10.78 | -1.55 % | $ 386 M | ||
|
Soliton, Inc.
SOLY
|
243 M | - | -1.42 % | $ 435 M | ||
|
Pulmonx Corporation
LUNG
|
54.1 M | $ 1.65 | -1.79 % | $ 67.1 M | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
2.61 B | - | -1.98 % | $ 98.3 M | ||
|
LivaNova PLC
LIVN
|
1.2 B | $ 73.8 | 1.04 % | $ 4.03 B | ||
|
Itamar Medical Ltd.
ITMR
|
229 M | - | 0.03 % | $ 1.58 B | ||
|
Misonix, Inc.
MSON
|
30.4 M | - | - | $ 462 M | ||
|
Myomo
MYO
|
11.4 M | $ 1.09 | 0.93 % | $ 45.6 M | ||
|
Neovasc
NVCN
|
52.2 M | - | - | $ 111 M | ||
|
Dynatronics Corporation
DYNT
|
3.26 M | - | 14.99 % | $ 929 K | ||
|
MiMedx Group
MDXG
|
257 M | $ 3.68 | 0.27 % | $ 544 M | ||
|
Electromed
ELMD
|
43.2 M | $ 37.72 | -3.55 % | $ 319 M | ||
|
Orthofix Medical
OFIX
|
450 M | $ 9.27 | -2.32 % | $ 367 M | ||
|
Butterfly Network
BFLY
|
196 M | $ 4.55 | -1.3 % | $ 1.12 B | ||
|
Intersect ENT, Inc.
XENT
|
550 M | - | - | $ 955 M | ||
|
Second Sight Medical Products
EYES
|
15.7 M | - | -0.97 % | $ 54.4 M | ||
|
Profound Medical Corp.
PROF
|
66.4 M | $ 6.81 | -1.3 % | $ 206 M | ||
|
GBS
GBS
|
2.81 M | - | -0.57 % | $ 7.12 M | ||
|
Globus Medical
GMED
|
4.57 B | $ 81.88 | -0.69 % | $ 11.1 B | ||
|
Insulet Corporation
PODD
|
1.52 B | $ 144.94 | 1.61 % | $ 10.2 B | ||
|
CONMED Corporation
CNMD
|
1.03 B | $ 35.7 | 0.51 % | $ 1.11 B | ||
|
Sintx Technologies
SINT
|
2.93 M | $ 2.24 | 1.82 % | $ 6.21 M | ||
|
Inspire Medical Systems
INSP
|
781 M | $ 41.36 | -3.97 % | $ 1.21 B | ||
|
Integer Holdings Corporation
ITGR
|
1.75 B | $ 89.38 | -0.74 % | $ 3.1 B | ||
|
Invacare Corporation
IVC
|
771 M | - | - | $ 24.7 M | ||
|
Edwards Lifesciences Corporation
EW
|
10.3 B | $ 86.47 | 0.59 % | $ 50.6 B | ||
|
TransMedics Group
TMDX
|
473 M | $ 67.2 | -0.93 % | $ 2.28 B |